• 3P and Buzzard Pharmaceuticals Enter Cancer Collaboration contractpharma
    May 08, 2021
    ​3P Biopharmaceuticals (3P) and Buzzard Pharmaceuticals (Buzzard) have entered into a partnership agreement for manufacturing of the potent IL-I inhibitor Isunakinra, a recombinant protein for cancer indications.
PharmaSources Customer Service